1. Home
  2. ONDS vs ALLO Comparison

ONDS vs ALLO Comparison

Compare ONDS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONDS
  • ALLO
  • Stock Information
  • Founded
  • ONDS 2014
  • ALLO 2017
  • Country
  • ONDS United States
  • ALLO United States
  • Employees
  • ONDS N/A
  • ALLO N/A
  • Industry
  • ONDS Telecommunications Equipment
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ONDS Telecommunications
  • ALLO Health Care
  • Exchange
  • ONDS Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • ONDS 326.8M
  • ALLO 363.1M
  • IPO Year
  • ONDS N/A
  • ALLO 2018
  • Fundamental
  • Price
  • ONDS $1.84
  • ALLO $1.43
  • Analyst Decision
  • ONDS Strong Buy
  • ALLO Strong Buy
  • Analyst Count
  • ONDS 2
  • ALLO 9
  • Target Price
  • ONDS $3.25
  • ALLO $8.44
  • AVG Volume (30 Days)
  • ONDS 20.1M
  • ALLO 3.5M
  • Earning Date
  • ONDS 08-13-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • ONDS N/A
  • ALLO N/A
  • EPS Growth
  • ONDS N/A
  • ALLO N/A
  • EPS
  • ONDS N/A
  • ALLO N/A
  • Revenue
  • ONDS $10,815,867.00
  • ALLO N/A
  • Revenue This Year
  • ONDS $243.35
  • ALLO N/A
  • Revenue Next Year
  • ONDS $118.81
  • ALLO $199.63
  • P/E Ratio
  • ONDS N/A
  • ALLO N/A
  • Revenue Growth
  • ONDS N/A
  • ALLO N/A
  • 52 Week Low
  • ONDS $0.54
  • ALLO $0.86
  • 52 Week High
  • ONDS $3.40
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • ONDS 47.75
  • ALLO 57.39
  • Support Level
  • ONDS $2.02
  • ALLO $1.21
  • Resistance Level
  • ONDS $2.20
  • ALLO $1.31
  • Average True Range (ATR)
  • ONDS 0.24
  • ALLO 0.10
  • MACD
  • ONDS -0.05
  • ALLO 0.02
  • Stochastic Oscillator
  • ONDS 12.59
  • ALLO 49.00

About ONDS Ondas Holdings Inc.

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: